论文部分内容阅读
血管紧张素转换酶抑制剂(即ACEI)近年来研制进展较快,已成为世界十大畅销药物中最畅销的四类心血管药物之一。多数新ACEI降压作用明显,用量小,作用时间持久,不良反应少,能够逆转血管肥厚和心脏功能异常,具有明显的抗动脉粥样硬化作用,改善高血压病人生活质量。现将临床选用的几种ACEI药物的药理基础及其临床药理学研究综述如下:
Angiotensin-converting enzyme inhibitors (ACEIs) have been rapidly developed in recent years and have become one of the top four best-selling cardiovascular drugs in the world’s top 10 best-selling drugs. Most new ACEI obvious antihypertensive effect, small dosage, long duration of action, adverse reactions, can reverse vascular hypertrophy and cardiac dysfunction, has obvious anti-atherosclerotic effect, improve the quality of life of hypertensive patients. Now clinical selection of several pharmacological basis of ACEI drugs and clinical pharmacology research summarized as follows: